T
TECregen
Biotech & Life Sciences · Basel, Switzerland · Founded 2023
Ligand-based therapies to restore thymus function and support lifelong immune health MoreLess
Ligand-based therapies to restore thymus function and support lifelong immune health
Valuation
$0–100M
Headcount
<100
Total funding
$10–50M
Unlock exact values
This page shows ranges. Dealroom has the exact numbers for TECregen and the history behind them.
Talent graph
TECregen's talent
Team profiled
1
named & role-tagged
Founders
Hidden — book a demo/100
quality score
Key operators
Hidden — book a demo
quality score
Potential founders
Hidden — book a demo
likely future founders
Startup mafia
Hidden — book a demo
alumni-founded startups
Talent movements
Hidden — book a demo in · Hidden — book a demo out
past 12 months
Source: Dealroom Talent Intelligence.
Global footprint
Where TECregen has talent and traffic
Workforce by country
4
countries with
team presence
team presence
🇨🇭 Switzerland63.6%
🇩🇪 Germany18.2%
🇬🇧 United Kingdom9.1%
🇫🇷 France9.1%
Market sentiment
What the market is saying about TECregen
An AI-synthesized read of the highest-engagement posts about TECregen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TECregen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.